Matthias Ganninger, Head of Business Technology, pRED, Roche

Scott Oloff, SVP of Data and Analytics, Roche

Sonia Houston Pichardo, Business Lead, MyStudyWindow, Boehringer Ingelheim

Discussion on how diversity, inclusion, and equity need to be taken into consideration when designing innovations, so that these innovations are adding value for all clinical trials participants and also opening up new opportunities for people to join clinical trials.

Ed Merivale, Sr. Clinical Operations Lead, Roche
Fay Scott, Founder & Co-Chair of the Race Equality Public Action Group, NIHR
Disa Lee Choun, Head of Integrated Clinical and Operational Analytics, Janssen
Ambily Banerjee, Head of Diversity, Equity, & Inclusion, Novartis

Moderator: Amri Johnson, Chief Executive Officer, Inclusion Wins

• A review of where the industry stands today in regards to Decentralized Clinical Trial (DCT) guidances, and why these are so important
• A discussion of Regulatory Barriers that may be slowing wider scale adoption

Scott Askin, Global Program Regulatory Director for Innovation, Novartis

Hilde Vanaken, Head Industry Leaders, Life Sciences & Healthcare, TCS

Sam Hariry, Global Head, Clinical Innovation, Novartis Institutes for BioMedical Research (NIBR)
Jeremy Wyatt, Chief Executive Officer, ActiGraph
Karine Smadja, Study Lead, pRED, Roche

Moderator: Dan Karlin, Chief Medical Officer, MindMed

The clinical trials patient experience can be augmented via technology in many different ways. This panel will explore some of the technology solutions that are having a positive impact on the clinical trial experience, and examine some of the underlying tenets that power them. Also learn where the industry is still lacking and what's next.

Gerard Randolph, Principal Scientist, pRED, Roche
Michael Rebhan, Associate Director, Precision Medicine, Novartis
Paul O'Donohoe, Scientific Lead, eCOA and Mobile Health, Medidata

Moderated by: Uta Sweere, Program Leader, pRED Clinical Operations, Roche

Data-driven selection of sites to increase inclusiveness & diversity of our trials.

Eric Malek, pRED Clinical Operations Data Scientist, Roche

A proof of concept pilot testing the use of blockchain technology in a live clinical trial setting to better engage and empower patients

Baldwin Mak, Digital Expert, Dept. of Clinical Operations, Boehringer Ingelheim

• The different innovations in clinical trials we have heard of today and more
• The regulatory principles that we need to take into account when innovating
• Innovation not as the goal, but as the enabler for faster patient access
• Co-creating with regulators and the ecosystem to enhance the uptake of innovations

Scott Askin, Global Program Regulatory Director for Innovation, Novartis
Kevin Obana, Special Projects Lead, HumanFirst
Kai Langel, Sr. Director, Strategy and Innovation, Global Regulatory Policy and Intelligence, Janssen
Matteo Lai, Co-founder and CEO, Empatica

Moderator: Lada Leyens, Regulatory Program Director, Roche

Astrid Kiermeier, VP, Global Head of EDIS (Enhanced Data and Insights Sharing), Roche
Peter Speyer, Head of Customer Success, data42, Novartis

Moderator: James Donohue, Trial Innovation Partner, Early Research & Development ClinOps, Roche

Data-driven design of clinical trials with recruitability and reduction of patient (and site) burden in mind.

Arianna Secco, Data Scientist, Roche
Todd Georgieff, External Engagement and Content Standards Lead, Roche

Rob Wilson, VP, Marketing Strategy, VivoSense
James Donohue, Trial Innovation Partner, Early Research & Development ClinOps, Roche
Andy Coravos, CEO and Co-Founder, HumanFirst

Moderator: Matthias Ganninger, Head of Business Technology, pRED, Roche